Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
5,687
result(s) for
"Nicholas, Christopher"
Sort by:
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post-traumatic stress disorder (PTSD). Changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score (primary endpoint) and Sheehan Disability Scale (SDS) functional impairment score (key secondary endpoint) were assessed by blinded independent assessors. Participants were randomized to MDMA-AT (
n
= 53) or placebo with therapy (
n
= 51). Overall, 26.9% (28/104) of participants had moderate PTSD, and 73.1% (76/104) of participants had severe PTSD. Participants were ethnoracially diverse: 28 of 104 (26.9%) identified as Hispanic/Latino, and 35 of 104 (33.7%) identified as other than White. Least squares (LS) mean change in CAPS-5 score (95% confidence interval (CI)) was −23.7 (−26.94, −20.44) for MDMA-AT versus −14.8 (−18.28, −11.28) for placebo with therapy (
P
< 0.001,
d
= 0.7). LS mean change in SDS score (95% CI) was −3.3 (−4.03, −2.60) for MDMA-AT versus −2.1 (−2.89, −1.33) for placebo with therapy (
P
= 0.03,
d
= 0.4). Seven participants had a severe treatment emergent adverse event (TEAE) (MDMA-AT,
n
= 5 (9.4%); placebo with therapy,
n
= 2 (3.9%)). There were no deaths or serious TEAEs. These data suggest that MDMA-AT reduced PTSD symptoms and functional impairment in a diverse population with moderate to severe PTSD and was generally well tolerated. ClinicalTrials.gov identifier:
NCT04077437
.
Results from the phase 3 placebo-controlled MAPP2 trial show that MDMA-assisted therapy reduces post-traumatic stress disorder (PTSD) symptoms and functional impairment in a diverse population with moderate to severe PTSD.
Journal Article
Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis
Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychological effects of these substances outside the period of acute intoxication have not been fully characterized. This study aimed to: (1) quantify the effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period; (2) test moderators of these effects; and (3) evaluate adverse effects and risk of bias.
We conducted a systematic review and meta-analysis of experimental studies (single-group pre-post or randomized controlled trials) that involved administration of psilocybin, ayahuasca, or LSD to clinical or non-clinical samples and assessed psychological outcomes ⩾24 h post-administration. Effects were summarized by study design, timepoint, and outcome domain.
A total of 34 studies (24 unique samples, n = 549, mean longest follow-up = 55.34 weeks) were included. Classical psychedelics showed significant within-group pre-post and between-group placebo-controlled effects on a range of outcomes including targeted symptoms within psychiatric samples, negative and positive affect-related measures, social outcomes, and existential/spiritual outcomes, with large between-group effect in these domains (Hedges' gs = 0.84 to 1.08). Moderator tests suggest some effects may be larger in clinical samples. Evidence of effects on big five personality traits and mindfulness was weak. There was no evidence of post-acute adverse effects.
High risk of bias in several domains, heterogeneity across studies, and indications of publication bias for some models highlight the need for careful, large-scale, placebo-controlled randomized trials.
Journal Article
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Introduction
Psilocybin is a psychedelic tryptamine that has shown promise in recent clinical trials for the treatment of depression and substance use disorders. This open-label study of the pharmacokinetics of psilocybin was performed to describe the pharmacokinetics and safety profile of psilocybin in sequential, escalating oral doses of 0.3, 0.45, and 0.6 mg/kg in 12 healthy adults.
Methods
Eligible healthy adults received 6–8 h of preparatory counseling in anticipation of the first dose of psilocybin. The escalating oral psilocybin doses were administered at approximately monthly intervals in a controlled setting and subjects were monitored for 24 h. Blood and urine samples were collected over 24 h and assayed by a validated liquid chromatography-tandem mass spectrometry (LC–MS/MS) assay for psilocybin and psilocin, the active metabolite. The pharmacokinetics of psilocin were determined using both compartmental (NONMEM) and noncompartmental (WinNonlin) methods.
Results
No psilocybin was found in plasma or urine, and renal clearance of intact psilocin accounted for less than 2% of the total clearance. The pharmacokinetics of psilocin were linear within the twofold range of doses, and the elimination half-life of psilocin was 3 h (standard deviation 1.1). An extended elimination phase in some subjects suggests hydrolysis of the psilocin glucuronide metabolite. Variation in psilocin clearance was not predicted by body weight, and no serious adverse events occurred in the subjects studied.
Conclusions
The small amount of psilocin renally excreted suggests that no dose reduction is needed for subjects with mild–moderate renal impairment. Simulation of fixed doses using the pharmacokinetic parameters suggest that an oral dose of 25 mg should approximate the drug exposure of a 0.3 mg/kg oral dose of psilocybin. Although doses of 0.6 mg/kg are in excess of likely therapeutic doses, no serious physical or psychological events occurred during or within 30 days of any dose.
Clinical Trials Identifier
NCT02163707.
Journal Article
Resting‐state functional connectivity of the human hippocampus in periadolescent children: Associations with age and memory performance
The hippocampus is necessary for declarative (relational) memory, and the ability to form hippocampal‐dependent memories develops through late adolescence. This developmental trajectory of hippocampal‐dependent memory could reflect maturation of intrinsic functional brain networks, but resting‐state functional connectivity (rs‐FC) of the human hippocampus is not well‐characterized for periadolescent children. Measuring hippocampal rs‐FC in periadolescence would thus fill a gap, and testing covariance of hippocampal rs‐FC with age and memory could inform theories of cognitive development. Here, we studied hippocampal rs‐FC in a cross‐sectional sample of healthy children (N = 96; 59 F; age 9–15 years) using a seed‐based approach, and linked these data with NIH Toolbox measures, the Picture‐Sequence Memory Test (PSMT) and the List Sorting Working Memory Test (LSWMT). The PSMT was expected to rely more on hippocampal‐dependent memory than the LSWMT. We observed hippocampal rs‐FC with an extensive brain network including temporal, parietal, and frontal regions. This pattern was consistent with prior work measuring hippocampal rs‐FC in younger and older samples. We also observed novel, regionally specific variation in hippocampal rs‐FC with age and hippocampal‐dependent memory but not working memory. Evidence consistent with these findings was observed in a second, validation dataset of similar‐age healthy children drawn from the Philadelphia Neurodevelopment Cohort. Further, a cross‐dataset analysis suggested generalizable properties of hippocampal rs‐FC and covariance with age and memory. Our findings connect prior work by describing hippocampal rs‐FC and covariance with age and memory in typically developing periadolescent children, and our observations suggest a developmental trajectory for brain networks that support hippocampal‐dependent memory.
The hippocampus is necessary for normal declarative (relational) memory, and the ability to form hippocampal‐dependent memories continues to develop through late adolescence. We studied the intrinsic (resting) functional connectivity of the hippocampus in two cross‐sectional samples (discovery and validation) of healthy periadolescent using a seed‐based approach, and measured the covariance of hippocampal functional connectivity with age and memory performance. In addition to predicted patterns of functional connectivity for hippocampus, we also observed novel, region‐specific variation in hippocampal functional connectivity with age and hippocampal‐dependent memory.
Journal Article
Cannabis use impacts pre‐stimulus neural activity in the visual cortices of people with HIV
People with HIV (PWH) use cannabis at a higher rate than the general population, but the influence on neural activity is not well characterized. Cannabis use among PWH may have a beneficial effect, as neuroinflammation is known to be a critical problem in PWH and cannabis use has been associated with a reduction in proinflammatory markers. Thus, it is important to understand the net impact of cannabis use on brain and cognitive function in PWH. In this study, we collected magnetoencephalographic (MEG) brain imaging data on 81 participants split across four demographically matched groups (i.e., PWH using cannabis, controls using cannabis, non‐using PWH, and non‐using controls). Participants completed a visuospatial processing task during MEG. Time–frequency resolved voxel time series were extracted to identify the dynamics of oscillatory and pre‐stimulus baseline neural activity. Our results indicated strong theta (4–8 Hz), alpha (10–16 Hz), and gamma (62–72 Hz) visual oscillations in parietal–occipital brain regions across all participants. PWH exhibited significant behavioral deficits in visuospatial processing, as well as reduced theta oscillations and elevated pre‐stimulus gamma activity in visual cortices, all of which replicate prior work. Strikingly, chronic cannabis use was associated with a significant reduction in pre‐stimulus gamma activity in the visual cortices, such that PWH no longer statistically differed from controls. These results provide initial evidence that cannabis use may normalize some neural aberrations in PWH. This study fills an important gap in understanding the impact of cannabis use on brain and cognitive function in PWH.
This work used a visuospatial processing paradigm in combination with magnetoencephalographic (MEG) imaging. Voxel‐level timeseries analyses were applied to study the impact of cannabis use on behavior and neural activity in people with HIV (PWH).
Journal Article